These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 27785772)
21. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Mullins CD; Rattinger GB; Kuznik A; Koren MJ Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915 [TBL] [Abstract][Full Text] [Related]
22. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874 [TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system. Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878 [TBL] [Abstract][Full Text] [Related]
25. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. O'Meara S; Cullum N; Majid M; Sheldon T Health Technol Assess; 2000; 4(21):1-237. PubMed ID: 11074391 [TBL] [Abstract][Full Text] [Related]
27. Polypills for the prevention of Cardiovascular diseases. Kolte D; Aronow WS; Banach M Expert Opin Investig Drugs; 2016 Nov; 25(11):1255-1264. PubMed ID: 27645895 [TBL] [Abstract][Full Text] [Related]
28. Modeling hard clinical end-point data in economic analyses. Kansal AR; Zheng Y; Palencia R; Ruffolo A; Hass B; Sorensen SV J Med Econ; 2013 Nov; 16(11):1327-43. PubMed ID: 24032651 [TBL] [Abstract][Full Text] [Related]
29. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. Rabar S; Harker M; O'Flynn N; Wierzbicki AS; BMJ; 2014 Jul; 349():g4356. PubMed ID: 25035388 [No Abstract] [Full Text] [Related]
30. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290 [TBL] [Abstract][Full Text] [Related]
32. Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. Maggioni AP; Calabria S; Rossi E; Martini N; Int J Cardiol; 2017 Nov; 246():62-67. PubMed ID: 28298250 [TBL] [Abstract][Full Text] [Related]
33. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? Aguiar PM; Lima TM; Storpirtis S J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796 [TBL] [Abstract][Full Text] [Related]
34. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations. Gialama F; Prezerakos P; Maniadakis N Appl Health Econ Health Policy; 2014 Feb; 12(1):41-9. PubMed ID: 24243517 [TBL] [Abstract][Full Text] [Related]
35. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762 [TBL] [Abstract][Full Text] [Related]
36. Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority. Bays HE; Dujovne CA Postgrad Med; 1992 Apr; 91(5):162-4, 167-8, 171-2 passim. PubMed ID: 1561158 [TBL] [Abstract][Full Text] [Related]
37. The clinical effectiveness and cost-effectiveness of second-eye cataract surgery: a systematic review and economic evaluation. Frampton G; Harris P; Cooper K; Lotery A; Shepherd J Health Technol Assess; 2014 Nov; 18(68):1-205, v-vi. PubMed ID: 25405576 [TBL] [Abstract][Full Text] [Related]
38. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229 [TBL] [Abstract][Full Text] [Related]
39. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register. Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306 [TBL] [Abstract][Full Text] [Related]